M S Carlino
Overview
Explore the profile of M S Carlino including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
1002
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Long G, Carlino M, McNeil C, Ribas A, Gaudy-Marqueste C, Schachter J, et al.
Ann Oncol
. 2024 Sep;
35(12):1191-1199.
PMID: 39306585
Background: Pembrolizumab significantly improved overall survival (OS) versus ipilimumab for unresectable advanced melanoma in KEYNOTE-006 (NCT01866319); 10-year follow-up data are presented. Patients And Methods: Patients with unresectable stage III or...
2.
Cass S, Tobin J, Seo Y, Gener-Ricos G, Keung E, Burton E, et al.
Ann Oncol
. 2023 Jul;
34(9):796-805.
PMID: 37414216
Background: Immune checkpoint inhibitors (ICIs) have revolutionized the management of advanced melanoma (AM). However, data on ICI effectiveness have largely been restricted to clinical trials, thereby excluding patients with co-existing...
3.
Piperno-Neumann S, Carlino M, Boni V, Loirat D, Speetjens F, Park J, et al.
Br J Cancer
. 2023 Jan;
128(6):1040-1051.
PMID: 36624219
Background: Up to 50% of patients with uveal melanoma develop metastases (MUM) with a poor prognosis and median overall survival of approximately 1 year. Methods: This phase I study evaluated...
4.
Dimitriou F, Namikawa K, Reijers I, Buchbinder E, Soon J, Zaremba A, et al.
Ann Oncol
. 2022 Jun;
33(9):968-980.
PMID: 35716907
Background: Mucosal melanoma (MM) is a rare melanoma subtype with distinct biology and poor prognosis. Data on the efficacy of immune checkpoint inhibitors (ICIs) are limited. We determined the efficacy...
5.
Long G, Arance A, Mortier L, Lorigan P, Blank C, Mohr P, et al.
Ann Oncol
. 2021 Oct;
33(2):204-215.
PMID: 34710571
Background: Antitumor activity of ipilimumab or BRAF ± MEK inhibitors (BRAFi ± MEKi) following pembrolizumab administration in melanoma is poorly characterized. Patients And Methods: In the phase III KEYNOTE-006 study,...
6.
Dimitriou F, Lo S, Tan A, Emmett L, Kapoor R, Carlino M, et al.
Ann Oncol
. 2021 Oct;
33(1):99-106.
PMID: 34687894
Background: We have previously shown that 75% of patients treated with programmed cell death protein 1 (PD-1) with or without CTLA4 who have not progressed by 1 year have complete...
7.
Owen C, Bai X, Quah T, Lo S, Allayous C, Callaghan S, et al.
Ann Oncol
. 2021 Apr;
32(7):917-925.
PMID: 33798657
Background: Immune-related adverse events (irAEs) typically occur within 4 months of starting anti-programmed cell death protein 1 (PD-1)-based therapy [anti-PD-1 ± anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4)], but delayed irAEs (onset...
8.
Sasson S, Zaunders J, Nahar K, Munier C, Fairfax B, Olsson-Brown A, et al.
Clin Exp Immunol
. 2020 Aug;
202(3):335-352.
PMID: 32734627
The aim of this study was to investigate the pathogenesis of combination ipilimumab and nivolumab-associated colitis (IN-COL) by measuring gut-derived and peripheral blood mononuclear cell (GMNC; PBMC) profiles. We studied...
9.
Owen C, Shoushtari A, Chauhan D, Palmieri D, Lee B, Rohaan M, et al.
Ann Oncol
. 2020 May;
31(8):1075-1082.
PMID: 32387454
Background: Anti-programmed cell death protein 1 (PD-1) antibodies (PD1) prolong recurrence-free survival in high-risk resected melanoma; however, approximately 25%-30% of patients recur within 1 year. This study describes the pattern...
10.
Lee J, Saw R, Thompson J, Lo S, Spillane A, Shannon K, et al.
Ann Oncol
. 2019 Mar;
30(5):815-822.
PMID: 30860590
Background: The outcomes of patients with stage III cutaneous melanoma who undergo complete surgical resection can be highly variable, and estimation of individual risk of disease recurrence and mortality remains...